EUCTR2019-001440-22-SE进行中（未招募）1 期
Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enzyme inhibitor, enalapril, in children and adults with C3 glomerulopathy - Reninblock-C3G
Skåne University Hospital0 个研究点目标入组 30 人开始时间: 2019年3月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Children = 6 years and adults.
- •2. Initial diagnosis of Dense Deposit Disease and C3 glomerulonephritis confirmed by kidney biopsy obtained not more than 2 years before the first dose of the study drug.
- •3. Either absence of treatment at the study start or ongoing treatment with aliskiren, ACEi, ARBs or immune suppressive medications (such as mycophenolate mofetil/MMF or corticosteroids)
- •4. Written informed consent has been given by:
- •a. the patient’s legal guardians if the patient is less than 15 years old
- •b. the patient and his/her legal guardians if the patient is = 15 but < 18years old
- •c. the patient if the patient is = 18 years old
- •5. Female subjects of childbearing potential must:
- •a. Understand that the study medication is expected to have a teratogenic risk
- •b. Agree to use a highly effective contraception during study drug therapy. This applies unless the subject is less than 18 years of age, has not had sexual debut and commits to sexual abstinence confirmed by a pregnancy test on every study visit.
- •c. Agree to have a pregnancy test before the start of study medication. This requirement also applies to women of childbearing age who practice complete and continued abstinence and adolescent girls after menarche.
- •d. Agree to have a pregnancy test every 3rd month including at the end of study treatment, except in the case of confirmed tubal sterilization. This requirement also applies to women of childbearing age who practice complete and continued abstinence and adolescent girls after menarche.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Known allergy to aliskiren or enalapril or substances contained in these preparations.
- •2. Angioedema caused by aliskiren or enalapril
- •3. Weight < 25 kg.
- •4. Glomerular filtration rate = 50 ml/min/1.73 m2 (measured by iohexol clearance) in children and = 30 ml/min/1.73 m2 in adults.
- •5. Rapid deterioration of kidney function during the latest year of the disease
- •5. Patients with a renal transplant.
- •6. Immune complex-mediated membranoproliferative glomerulonephritis (such as in HIV infection, hepatitis, SLE).
- •7. Females who breastfeed, are pregnant or planning to become pregnant during the study.
- •8. Co-morbidity such as malignancy, congestive heart failure, recent myocardial infarction.
- •9. Mental incapacity or language barriers to understand the contents of the study design.
- •10. Simultaneous use of another complement-antagonist (such as eculizumab). Eculizumab must be discontinued and complement activity normalized before the start of study drug.
- •11. Simultaneous use of aliskiren or enalapril with cyclosporine or nonsteroidal anti-inflammatory drugs (NSAID).
研究者
相似试验
招募中
1 期
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyCTIS2024-515892-36-00Region Skane30
进行中（未招募）
1 期
Proof-of-concept study for BIVV020 in chronic inflammatory demyelinating polyneuropathy (CIDP)Chronic inflammatory demyelinatingpolyneuropathyMedDRA version: 20.0Level: LLTClassification code 10077384Term: Chronic inflammatory demyelinating polyneuropathySystem Organ Class: 100000004852EUCTR2020-004006-54-FRSanofi-Aventis Recherche & Développement90
进行中（未招募）
1 期
An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to Positon Emission Tomography (PET) value modification in patients with early stage HER2 positive breast cancer - AVATAXHERearly stage HER2 positive breast cancerMedDRA version: 12.0Level: PTClassification code 10057654Term: Breast cancer femaleEUCTR2009-013410-26-FRROCHE SAS156
招募中
2 期
Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.MalariaPACTR201801002894101ovartis Pharma AG150
进行中（未招募）
不适用
A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.Patients aged 6 months to <18 years, presenting with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.MedDRA version: 14.1Level: LLTClassification code 10065868Term: Embryonal rhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10061526Term: Malignant mesenchymomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065867Term: Alveolar rhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10058387Term: Schwannoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10039494Term: Sarcoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10039024Term: Rhabdomyosarcoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10039022Term: RhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10039026Term: Rhabdomyosarcoma previously untreatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10024189Term: LeiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10042864Term: Synovial sarcoma metastaticSystem Organ Class: 10029104 - NeoplasmEUCTR2007-005017-19-Outside-EU/EEAF. Hoffmann-La Roche Ltd150